IN8bio, Inc. (NASDAQ:INAB – Get Free Report) was the target of a significant decrease in short interest in August. As of August 31st, there was short interest totaling 90,842 shares, a decrease of 35.1% from the August 15th total of 139,903 shares. Based on an average daily trading volume, of 55,295 shares, the days-to-cover ratio is presently 1.6 days. Currently, 1.1% of the company’s stock are sold short.
Analysts Set New Price Targets
Several equities analysts have weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating on shares of IN8bio in a research note on Thursday, June 4th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.00.
Check Out Our Latest Stock Analysis on INAB
Institutional Inflows and Outflows
IN8bio Stock Up 0.9%
IN8bio stock opened at $1.08 on Friday. IN8bio has a 52 week low of $0.88 and a 52 week high of $2.73. The company’s 50 day moving average price is $1.13 and its two-hundred day moving average price is $1.40. The stock has a market cap of $10.65 million, a P/E ratio of -0.67 and a beta of 0.30.
IN8bio (NASDAQ:INAB – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.09. On average, equities analysts anticipate that IN8bio will post -1.49 EPS for the current year.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.
See Also
- Five stocks we like better than IN8bio
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.
